Victoire Laurenty
Angel Investor · at Wendel Growth
Paris, France
Victoire Laurenty is a Series A investor at Wendel Growth in Paris focused on Biotechnology and Pharmaceutical. Victoire joined Kerala to lead dealflow operations after starting her career in strategy consulting at L.E.K. Consulting (3y) and in the Ardian Growth investment team (1,5y).At L.E.K. she executed numerous strategic due diligences for various private equity funds and several corporate strategy assignments.At Ardian Growth, Victoire hasparticipated to more than 5 deals and reinvestments in the digital and IT sector including Planiware, Clever Age, TabMo and Uptoo.Victoire graduated from Telecom Paristech, and holds a MSc in Applied Mathematics from the London School of Economics.Past and current Boards: Ouihelp
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Victoire Laurenty invests in
Stages Victoire Laurenty invests in
Countries Victoire Laurenty invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
- Machine Learning 1 (50%)
- Quantum Computing 1 (50%)
- Artificial Intelligence 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AQEMIA is a pharmatech company developing a drug discovery platform to discover new drugs for specific therapeutic targets. Its platform combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a growing pipeline of new drug candidates. The company utilizes advanced techniques, including generative AIand atomic scale physics, to design novel drugs tailored for specific therapeutic targets. | $38M / Series A / Dec 10, 2024 | ||
| AQEMIA is a pharmatech company developing a drug discovery platform to discover new drugs for specific therapeutic targets. Its platform combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a growing pipeline of new drug candidates. The company utilizes advanced techniques, including generative AIand atomic scale physics, to design novel drugs tailored for specific therapeutic targets. | $32.5M / Series A / Jan 30, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Victoire Laurenty invest in?
Victoire Laurenty invests primarily in Biotechnology, Pharmaceutical and Machine Learning startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Victoire Laurenty?
Public channels for Victoire Laurenty include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Victoire Laurenty last invest?
The most recent investment recorded for Victoire Laurenty closed in Dec 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
